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Abstract
 Advances in genomic technology and an increase in the number of gene-disease 
associations have helped reduce the number of individuals living without a diagnosis. 
Whole exome sequencing (WES) analyzes the entire human exome in an attempt to 
determine if there is a molecular etiology for individuals who remain undiagnosed after 
other clinical or molecular investigations. Still, WES leaves most individuals 
undiagnosed, resulting in feelings of disappointment and uncertainty. Individuals who 
remain undiagnosed after WES can subsequently undergo WES reanalysis later due to 
improvements in bioinformatics, software updates, and an increase in known gene-
disease associations. This is the first study, to the investigator’s knowledge, which 
investigates parental perspective of those undergoing the most current genetic testing 
available. This study recruited parents of undiagnosed individuals who have completed 
WES and subsequent reanalysis through the Greenwood Genetic Center to investigate 
their response to and experience with WES reanalysis while on their diagnostic odyssey. 
Six semi-structured interviews were conducted, recorded, and transcribed verbatim. 
Transcripts were analyzed using grounded theory and assigned codes to meaningful 
segments of text. Results showed most participants had lower expectations of reanalysis 
compared to the initial WES and felt it would not lead to a diagnosis. Most participants 
responded to nondiagnostic reanalysis results with feelings of disappointment and worry 
about the future. However, some exhibited a difference in the degree to which they 
negatively responded. Most participants recognized that reanalysis has been unhelpful for 
v 
their child but expressed willingness to contribute to science if it will assist future 
individuals on a diagnostic odyssey. Despite feelings that reanalysis was unhelpful, most 
participants would consider reanalysis again for their child. Considering the apparent 
comprehensive nature of genomic testing, these results show there is a need to balance 
hope and realistic expectations during counseling and consent of WES reanalysis. In 
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1.1 A diagnosis 
The journey and search for a diagnosis is referred to in the clinic and literature as 
a “diagnostic odyssey.” The process of a diagnostic odyssey has been defined as “the 
time between when a parent or provider first becomes concerned about a child’s 
development and a diagnosis is eventually reached” (Carmichael, Tsipis, Windmueller, 
Mandel, & Estrella, 2015). All individuals who have received a diagnosis have been on 
varying lengths of a diagnostic odyssey. For some, their diagnostic odyssey may last for 
months or years while others may remain undiagnosed in their lifetime. 
There are many different times during the lifespan when an individual can be 
diagnosed. The earliest time one might receive a diagnosis is prenatally. For example, a 
diagnosis of Down syndrome can be made during the first trimester of pregnancy through 
a procedure known as chorionic villus sampling (CVS). Using the tissue obtained through 
CVS, a chromosomal karyotype is completed to assess the baby’s number of 
chromosomes.  
Postnatally the pursuit of a diagnosis begins with clinical recognition and 
evaluation of an individual’s symptoms. If a condition is not readily suspected or 
diagnosed, an individual may spend time as an in- or out-patient, undergoing various 
imaging, clinical or laboratory tests, and consults with experts. In general, individuals 
who undergo a diagnostic odyssey have unexplained, medically complex features. 
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In the new age of technology, many will undergo genetic testing as part of their 
diagnostic odyssey. Genetic testing can help clarify a clinical diagnosis or give an 
individual a molecular diagnosis when a clinical diagnosis is unclear. A molecular 
diagnosis means that the diagnosis has a known biological cause that can be tested. This 
is different from a clinical diagnosis which describes physical features but the diagnosis 
does not necessarily have a known biological cause that can be molecularly detected. 
Typically, to make a clinical diagnosis there are standardized criterion that must be met 
and published guidelines that are followed (Makela, Birch, Friedman, & Marra, 2009). 
When a molecular and clinical diagnosis has been thoroughly researched, the medical 
field has prognostic and anticipatory information to guide the family and dictate 
treatment. Although some molecular diagnoses may be well researched, many can be rare 
or newly discovered and, therefore, not have as much clinical information available.  
A third type of diagnosis is known as a “working diagnosis.” A working diagnosis 
is used when a clinical or molecular diagnosis has not been confirmed, but there may be 
suspicion of a condition (Lewis, Skirton, & Jones, 2010). Even though a condition has 
not been confirmed, a working diagnosis can be beneficial because the individual may 
have the ability to obtain services and access to support groups (Lenhard, Breitenbach, 
Ebert, Schindelhauer-Deutscher, & Henn, 2005). 
1.2 The impact of a diagnosis  
Receiving a diagnosis can help provide families with emotional, medical, and 
educational benefits. Many studies have found that a diagnosis can give a family a sense 
of closure, help guide family planning, and provide the recurrence risk in future children 
(Carmichael et al., 2015; Lenhard et al., 2005; Graungaard & Skov, 2007). An additional 
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benefit of receiving a diagnosis includes improving the psychosocial outcomes for 
individuals and families affected by disabilities (Rosenbaum, 1988). Moeschler and 
Shevell (2014) explain the effect of receiving a diagnosis as a “healing touch” that 
bolsters well-being. Carmichael and colleagues (2015) found that receiving a diagnosis 
lifted some of the emotional burden associated with being undiagnosed. Emotional 
burden was lessened because a diagnosis validated parental concerns, justified their 
pursuit of a diagnosis, gave them access to certain support groups, and allowed them to 
properly plan for the future.  
How an individual receives a diagnosis affects satisfaction with the medical field. 
A qualitative study interviewing parents of physically and mentally disabled children 
who recently received a diagnosis found that the process of receiving a diagnosis and the 
certainty of the stated diagnosis strongly influenced the parents’ experiences and abilities 
to cope with a diagnosis. Themes that influenced satisfaction with the diagnostic process 
depends on the context. This includes the setting of where the information was given, the 
timing of the information, and level of information related to the parents’ readiness to 
receive the information (Graungaard & Skov, 2007). These results showed that there are 
many variables that influence a diagnostic odyssey, making it a complex time for 
families.  
The diagnosis of a rare condition may happen years after symptoms appear and 
many tests later. The natural history, prognosis or medical management of rare conditions 
may not be known. Some families prefer a diagnosis, even if it involves a poor prognosis, 
rather than remain uncertain (Makela et al., 2009; Stewart & Mishel, 2000). In addition to 
preferring a diagnosis rather than not, many parents understand that receiving a specific 
 
4 
diagnosis may not change medical management or have a known cure. Notably, these 
parents recognized the importance of their child’s test results for future medical research 
(Rosenthal, Biesecker, & Biesecker, 2001).  
1.3 Living without a diagnosis 
Unfortunately, some may never have an end to their diagnostic odyssey. One 
study found between 30 and 50% of individuals with intellectual disability go without a 
known etiology (Daily, Ardinger, & Holmes, 2000). According to The Rare and 
Undiagnosed Network (2017), one in ten individuals are living with a rare or 
undiagnosed disease; half of these individuals are children. 
Living without a diagnosis can be challenging and have various adverse effects 
for individuals and their families. Effects may include the inability to receive certain 
medical or educational services provided and covered by insurance or the state. In 
addition, living with an undiagnosed condition may involve a lack of direct treatment, 
anticipatory guidance, and information on prognosis (Carmichael et al., 2015; Lewis et al. 
2010). One study found that families may feel emotionally isolated, unable to connect 
with others living with a similar diagnosis, and have difficulty in coping with an 
uncertain future (Graungaard & Skov, 2007). Overall, many studies have repeatedly 
reported time spent undiagnosed as stressful, overwhelming, and involving various 
negative emotions. This is a result of added medical care for their child and required 
medical appointments. Additionally, feelings of being out of control may result in 
emotional distress and burden (Lewis et al., 2010). 
Those on a diagnostic odyssey spend much of their time wondering how to plan 
and manage medical concerns (Rosenthal et al., 2001). A recent study investigated 
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uncertainty and lack of control in parents of children living with various medical 
conditions, some of which were undiagnosed. Lower levels of optimism and higher levels 
of uncertainty were reported in individuals who perceived less control over their child’s 
undiagnosed condition. Although parents felt they did not have control overall, they felt 
in control of some aspects of their child’s condition. The aspects they felt they could 
control included information and decision making, advocacy, the child’s comfort, and 
self-care (Madeo, O’Brien, Bernhardt, & Biesecker, 2012).  
The emotional burden associated with being undiagnosed shows the importance 
of establishing a strong support system for these individuals and their families as they 
search for a diagnosis. Although they may not have direct access to certain medical or 
support services, there are a handful of online support groups created specifically for 
those who are undiagnosed or diagnosed with rare conditions. One online support group, 
Syndromes Without a Name (SWAN), is nationally available and officially became a 
nonprofit organization in the United States in 2006. The site allows families facing 
similar challenges to connect either through the SWAN website or Facebook group. A 
few goals of the group are to address the lack of information associated with being 
undiagnosed, offer emotional support, and help with psychosocial concerns such as 
isolation, guilt, or helplessness (Syndrome Without a Name, 2017).  
A second online support group known as the Rare & Undiagnosed Network 
(RUN) aims to address similar issues. Their mission is to “empower rare and 
undiagnosed patients and their families with genomic information through community, 
advocacy, networking, and support” (Rare and Undiagnosed Network, 2017). Like 
SWAN, families can share their stories, and RUN helps give them a sense of community. 
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These two organizations are wonderful resources for families on a diagnostic odyssey and 
dealing with uncertainty surrounding their child’s health.  
Not only is a diagnostic odyssey emotionally exhausting, but it is financially 
costly as well. The cost of discovering a diagnosis may include more expensive, large-
scale genomic sequencing that is recommended as second-tier testing completed after 
cheaper and targeted testing is negative. Genomic testing is broad, nonspecific testing 
that looks at a much larger part of the human genome than targeted genetic testing. A 
recent study found that patients who had previously completed basic and complex 
investigations searching for a diagnosis could be spending up to $21,000 (Stark et al., 
2017). In this study “basic investigations” referred to standard clinical assessments 
including biochemical, imaging, and neurophysiological studies while “complex 
investigations” referred to non-standard testing that may have included complex 
biochemical or genetic testing.  
1.4 New technologies and genomic sequencing 
In recent years, major medical strides and technological advancements have 
worked towards decreasing the number of undiagnosed individuals and increasing 
knowledge of rare conditions. To aid in diagnosing medically complex cases, the 
Undiagnosed Diseases Network (UDN) was created in 2008. The UDN is a multisystem 
research study funded by the Nation Institute of Health (NIH) known as the NIH 
Undiagnosed Disease Program (UDP). The purpose of the UDP is to gather clinical and 
research specialists working in the U.S. with the common goal to solve medical mysteries 
using new technology (Gahl, Wise, & Ashley, 2015). Thirteen research and clinical sites 
contribute to the UDP including Duke Medicine, Harvard Teaching Hospital, Stanford 
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Medicine, and Vanderbilt University Medical Center (Undiagnosed Diseases Network, 
2017). These centers collaborate with each other and their patients to understand better 
the origins of disease. By publishing their work, the UDN is making great efforts to 
improve the level of diagnostics and care in hopes to relieve some of the burden felt by 
individuals and parents of those living with undiagnosed conditions. 
Since the publication of the completed human genome sequence in 2004, decrease 
in the cost of sequencing DNA has changed the landscape of clinical testing and is a 
driving force behind changes in genetic testing practice guidelines (International Human 
Genome Sequencing Consortium, 2004). The initial sequencing of the human genome 
utilized a technique known as Sanger sequencing. Although Sanger sequencing still is 
used, most laboratories now heavily rely on a more recently developed sequencing 
technique known as Next Generation Sequencing (NGS). NGS allows for rapid 
sequencing of single and multiple genes at a reduced cost and faster turnaround time 
(TAT) compared to traditional Sanger sequencing (Mardis, 2008). The first commercially 
available NGS sequencer, known as the 454 Life Sciences Next Generation Sequencing 
system, was launched in 2005 (Van Dijk, Auger, Jaszczyszyn, & Thermes, 2014). Since 
then, data output has more than doubled each year and the cost of genomic sequencing 
has decreased at a rate faster than anticipated by Moore’s Law. Since the cost of genomic 
sequencing is decreasing more quickly than anticipated, its clinical use is becoming more 
accessible (Sarda & Hannenhalli, 2014). 
When DNA sequencing first was offered, clinical testing was limited to a single 
gene or small collection of genes. A gene is a unit of genetic material that provides the 
instructions for our bodies. Genes are housed within the human genome. Available 
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testing has expanded to include multi-gene tests, known as panels. Panel testing targets 
specific genes that are indicated when clinical evaluation suggests a diagnosis. Panels can 
be thought of as “first-tier” testing because they are the most clinically efficient in terms 
of cost and diagnostic yield.  
Genetic technology now has allowed the ability to clinically offer analysis of an 
individual’s entire genome. The entire human genome consists of approximately 20,000 
genes and therefore, encompasses a complete set of DNA (Ezkurdia et al., 2014). 
Genomic sequencing is currently recommended when clinical evaluation is unclear or 
uncertain, the genes involved are generally unknown, the patient has tested negative 
using other first-tier testing options, or a broader testing approach is warranted. These 
broader approaches can include whole genome sequencing (WGS) or whole exome 
sequencing (WES).  
Whole genome sequencing and WES are sequencing techniques that use NGS 
technologies. Rare or unexpected diagnoses often are revealed by WGS and WES, which 
sequence the entire human genome and exome, respectively. The Human Genome Project 
found that the human genome contains a total of about three billion base pairs. The 
human exome is the portion of the human genome which codes for proteins made within 
the body and accounts for less than one percent of the genome (International Human 
Genome Sequencing Consortium, 2004). This estimates the human exome to 
approximately 60 million base pairs split across about 180,000 exons (Ng et al., 2009).  
1.5 Whole exome sequencing  
Laboratory procedure involved in genomic sequencing is complex. In simplified 
steps, WES involves the lab’s receipt of the patient’s specimen, usually a blood sample, 
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followed by DNA extraction. The exome then is targeted, enriched, and sequenced by 
NGS (White et al., 2017). One of the more complex, and last steps is variant 
classification and annotation. In previous years, variant classification and annotation 
encompassed a significant amount of WES result analysis. In 2014, it was estimated that 
20 to 40 hours of expert time was needed to analyze a clinical exome (Dewey et al., 
2014). Recent improvements in bioinformatics tools, updated analysis software, and new 
public variant databases have drastically reduced the time spent analyzing genomic data 
(Stenson et al., 2017; Wright et al., 2018). 
Variant analysis involves filtering through and deciphering which detected 
variant(s) best matches with the patient’s clinical features, or phenotype. In this way, 
WES and WGS results are phenotypic-driven. This means that labs will report variants 
that potentially explain what is clinically indicated. For example, if a patient presents 
with many unexplained features such as seizures, low muscle tone, strabismus, and a 
congenital heart defect, only variants associated with any of those features are reported.   
To help standardize variant classification, the American College of Medical 
Genetics and Genomics (ACMG) in collaboration with the Association for Molecular 
Pathology (AMP) has published standards and guidelines on variant classification and 
interpretation that laboratories can use when analyzing genomic data. A variant must 
meet certain criterion to be correctly classified. Included in the criterion are specific 
variant evidence such as population data, computational (in silico) data, functional data, 
symptomatic data, etc. The five standard categories of variants detected by WES include 
‘pathogenic’, ‘likely pathogenic’, ‘uncertain significance’, ‘likely benign’, and ‘benign’. 
A variant is classified as pathogenic or likely pathogenic when evidence suggests the 
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change is causative of the patient’s features. A variant of uncertain significance is 
classified as a change for which there is not enough data to support its classification as 
likely pathogenic or likely benign. Finally, the classification of likely benign or benign is 
justified when evidence indicates the change is not disease-causing (Richards, Aziz, Bale, 
Das, & Gastier-Foster, 2015). 
Based on the laboratories’ classification of variants detected, laboratories will 
then classify genomic test results into four categories. Result classification is separate 
from variant classification but is influenced by the type of variant detected. The first type 
of result is a positive, or definitive result, meaning the lab found a pathogenic or likely 
pathogenic variant in the patient resulting in a molecular diagnosis. The second result is a 
possible, or probable diagnosis. This means the lab detected a variant that is located in a 
known disease-causing gene possibly associated with the patient’s clinical features. A 
third result is a variant in a new ‘candidate gene’ not previously associated with human 
disease but suspected to be disease-causing based on the nature of the variant and the 
known function of the gene product. The final type of result is a negative result meaning 
the lab found no variant associated with disease or the phenotype of the patient 
(Williams, Retterer, Cho, Richard, & Juusola, 2016). This final result leaves the patient 
undiagnosed. 
1.6 Clinical implementation of whole exome sequencing 
Genetic testing is currently at a turning point with the advent of genomic 
sequencing. Although the cost of DNA sequencing is decreasing, interpretation of 
genomic sequencing data continues to become more complex and time-consuming due to 
the large amount of data generated. Whole genome sequencing of a single sample 
 
11 
generates about 3 million variants that are different from the human reference genome 
while WES generates a range of 30,000 to 70,000 variants per sample (Hedge et al., 
2017). Although WGS can be ordered clinically, it is not utilized as frequently as WES 
because it is more expensive and results in a greater amount of data that requires much 
more analysis and interpretation than WES.  
There have been several publications addressing the clinical utility and 
implementation of WES. Challenges identified in clinical implementation include cost, 
TAT, lack of clinical guidance, variant interpretation, and potential incidental findings 
(Bertier, Hetu & Joly, 2016; Iglesias et al., 2014; Williams, Cashion, & Veenstra, 2015). 
There has only been one publication suggesting comprehensive guidelines for the 
implementation of exome sequencing in the clinic (Matthijs et al., 2015).  
Recently, studies have investigated the utility of clinically offering WES as first-
tier testing (Krabbenborg et al., 2016; Stark et al., 2016; Tan et al., 2017). A 2015 study 
compared three different tests which utilized Next Generation Sequencing (NGS). Sun 
and colleagues (2015) used nine samples to investigate the differences between gene 
panels, WES, and WGS data from patients with intellectual disability. The study looked 
at 537 gene panels targeted toward intellectual disability. The largest limitation of panel 
testing is that they are targeted and only successful if the causative gene is on the panel. 
Interestingly, WES did not miss any of the variants detected by the more comprehensive 
WGS. Although they recognized that panel testing is the cheapest and WGS is technically 
the most inclusive test, they concluded that WES was the best test option when clinical 
indication involves intellectual disability. WES analyzes more genomic material and will 
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find variants in genes not included on targeted panels. WES is a reasonable alternative to 
WGS due to cost, TAT, and ability to clinically implement the tests.  
The economic cost of WES has been a large challenge for clinical 
implementation. When WES first was offered in 2011 the cost ranged between $4,500 
and $9,000 (Atwal et al., 2014). Since then, the cost of WES has decreased. Stark and 
colleagues (2017) investigated the cost effectiveness of WES and quoted the cost of a 
clinical WES as approximately $2,412. A review of articles published between 2014 and 
2015 found that the cost of WES was thought to be too expensive for use as standard 
testing (Bertier et al., 2016).  
In addition to cost, the length of time waiting for results is an important aspect of 
WES. In 2014, the TAT for WES ranged from 11 to 21 weeks with an average of 18 
weeks (Atwal et al., 2014). Since 2014, TAT has substantially decreased in 2017 to an 
average of 40 days in cases where individuals needed results quickly (Bourchany et al., 
2017). The high cost and lengthy TAT is due partly to the process and analysis of WES 
variants detected by the laboratory.  
Practical concerns regarding patient education and consent in pretest counseling 
are a barrier to clinically offering WES (Iglesias et al., 2014). Due to the vast amount of 
data analyzed in WES, pre-test counseling can be extensive. In many clinics, a genetic 
counselor is the medical professional working with these families. Patients and families 
pursuing WES should be counseled on many aspects including TAT, possible results, 
yield of testing, insurance coverage, cost, updates of test results or reanalysis, and impact 
on clinical care. A recent study found that parents were able to accurately describe their 
child’s WES results and communicate the implications (Tolusso et al., 2016). This shows 
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that genetic counseling in that study had provided appropriate informed consent and 
follow-up for WES despite its complexity.  
Another important aspect lending to the challenges of offering clinical genomic 
testing is the possibility of incidental or secondary findings. Guidelines introduced by the 
ACMG in response to challenges associated with incidental findings (Green et al., 2013 
& Kalia et al., 2017). Incidental findings pertain to results discovered after completion of 
filtering and segregation analysis but are not related to the primary indication for testing. 
Secondary findings pertain to results not related to the primary indication but that are 
sought purposely during the analysis of the test results (Weiner, 2014). Importantly, both 
incidental and secondary findings may have health, reproductive, or personal importance 
for the patient or the family. Different from incidental findings, secondary findings are 
sought because they are medically actionable and have published health management 
guidelines. More time may be spent informing patients about the possibility of secondary 
findings since these results may be more medically actionable than other variants 
detected (Tolusso et al., 2016).  
The ACMG Working Group published a secondary findings list of 59 genes and 
26 conditions that clinical laboratories have an obligation to test for during the course of 
WES and WGS (Green et al., 2013; Kalia et al., 2017). The list includes childhood- and 
adult-onset conditions such as Li-Fraumeni syndrome, PTEN hamartoma tumor 
syndrome, Hereditary Breast and Ovarian Cancer syndrome, and Marfan syndrome. 
Certain variants found in any of these conditions should be reported by the laboratory, 
regardless of the indication for testing. This is grounded in the duty to prevent harm by 
warning patients and their families about medically actionable information. There is 
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controversy surrounding this aspect of genomic testing and if the duty to report these 
findings supersedes patient or parent autonomy. On the other hand, health providers may 
be liable if they fail to report secondary or incidental findings that could have prevented 
disease or changed medical management. In 2014, ACMG revised recommendations to 
state that patients should be given the option to opt-out before the testing takes place. 
That way the patients do not receive results that they did not desire (Clayton et al., 2013).  
1.7 Diagnostic yield of whole exome sequencing  
Large scale studies and laboratory data show that WES can find a disease-causing 
pathogenic variation in approximately 25-40% of individuals, leaving up to 75% of 
individuals pursuing WES undiagnosed after completion (Baldridge et al., 2017; Farwell 
et al., 2014; Lee et al., 2014; Yang et al., 2014). Farwell and colleagues (2014) found the 
highest diagnostic rates were observed among patients with ataxia (44%), multiple 
congenital anomalies (36%), and epilepsy (35%).  
Because WES does not yield a diagnosis for patients in up to 75% of cases, the 
limitations of WES and its inability to detect causative genetic variants in severely 
affected individuals is important to understand. In general, WES sequences exons and 
short exon-flanking regions, including consensus splice-site sequences (Hedge et al., 
2017). The test will not detect genetic changes located outside of these regions. This 
includes non-protein coding regions such as introns, variants located in regulatory units, 
transcriptional units or mitochondrial DNA. Alterations that do not affect the sequence of 
the DNA, such as chromosomal rearrangements, inversions, trinucleotide repeats, or 
epigenetic changes will not be detected as well (Need & Goldstein, 2016).  
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Labs often analyze WES as “trios”, which includes sequencing three samples; the 
patient’s and both biological parents’ samples, or the patient’s and two other closely 
related relatives’ samples. The lab can then compare the patient’s findings to their 
biological parents or other relative. Although not essential, a trio allows for the lab to 
determine if the variant is de novo, or not inherited from either parent. The diagnostic rate 
of WES when run as a trio has been reported as 37%, specifically done on the patient and 
two first-degree relatives. This was compared with a singleton WES diagnostic rate of 
21% (Farwell et al., 2014). 
Importantly, having both parental samples may allow for the detection of certain 
genetic alterations such as uniparental disomy (UPD). Uniparental disomy is an atypical 
situation where a child has two copies of the same chromosome from one parent, as 
opposed to the expected one from each parent (Bis et al., 2017). When both parental 
samples are not available, WES would not be able to detect UPD.   
Another reason WES may not detect a causative variant involves lab processes. 
Differences in laboratory bioinformatics, variant filtration techniques and, despite 
standardized guidelines, the definition of a pathogenic variant may all impact detection 
and yield. The laboratory will analyze all variants found in a patient through its own 
filtration system to determine which variant best matches the patient’s phenotype. If a 
variant is unassociated with the clinical indications, the variant may not be reported. It is 
possible some novel, yet causative, variants go unreported since WES results are 
phenotypic-driven. In addition, depending on the variant’s classification (i.e. pathogenic, 
benign, etc.) the result may or may not give the patient a straight forward diagnosis or 
answer. For example, a variant found in a potential candidate gene, for a new genetic 
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condition, will likely have little known data and have little impact on clinical care (Lee et 
al., 2014). 
Additional components that affect WES diagnostic yield include data mining, 
gene discovery, newly available clinical information, and increasing collaborations 
between laboratories, clinicians and researchers (Wenger, Guturu, Bernstein, & Bejerano, 
2017; Wright et al., 2018). Data mining refers to the process whereby laboratories sift 
through literature and research any new or helpful information on the detected variant. 
Data mining may also include searching for previously reported genetic variants using 
databases such as ClinVar (ncbi.nlm.nih.gov/clinvar), GeneMatcher (genematcher.org) 
and PhenomeCentral (phenomecentral.org). These sites match laboratories and institutes 
with one another when they both have identified individuals with a variant in the same 
gene, and with matching clinical features. Knowledge of other labs and individuals with 
the same rare variant can help the healthcare providers to properly explain the variant to 
the patient. Furthermore, finding others who have seen the same variants can aid in 
classifying a variant.  
Genomic sequencing has lent itself to the revelation of new disease phenotypes 
but has also resulted in producing diagnostic dilemmas caused by genes previously 
unknown to cause human disease. Resources such as GeneMatcher and PhenomeCentral 
have likely helped establish some of these gene-disease associations in combination with 
new technology, such as WGS and WES. As White and colleagues (2017) conclude, the 
field must “...share data, clinical findings, and experiences...” to successfully implement 
an influential tool such as genomic sequencing.  
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It is evident that such rapidly evolving genetic research and sharing would have a 
strong impact on the diagnostic yield of WES. As of 2014, 23% of positive WES results 
were found within genes characterized since 2012 (Farwell et al., 2014). In October of 
2004 a database of human genes and genetic disorders and traits, known as the Online 
Mendelian Inheritance in Man (OMIM), listed 1,636 phenotypes with a known molecular 
cause. Eleven years later in October of 2015, OMIM listed 4,570 Mendelian disorders 
with gene-disease associations. This was an increase of about 266 entries per year over 
the past eleven years (Wenger, Guturu, Bernstein, & Bejerano, 2017).  
1.8 Whole exome sequencing and reanalysis 
Although use of genomic testing has helped expand clinical genetics, this is often 
not the final chapter in a patient’s diagnostic odyssey. For those patients who do not 
receive a diagnosis from initial WES testing, reanalysis of results may be an option. 
Reanalysis is accomplished not by obtaining a second blood sample, but by reexamining 
the initial variants found through a lab’s analysis bioinformatics system. Although there 
are published ACMG guidelines on variant classification in WES, there are currently no 
published guidelines on WES reanalysis.  
Given the fast pace of gene discovery, it is important to realize the need to 
thoroughly reanalyze WES results (Zhu et al., 2015). One rationale behind a 
reexamination of the same data after a significant amount of time has passed is that the 
number of gene-disease associations has improved and thus the likelihood of identifying 
a causative variant is increased. Other factors that allow for reanalysis include 
improvement to lab bioinformatics and changes in variant annotation over time. As 
variant databases grow, laboratories have the ability to update reports and variant 
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classifications. According to the published ACMG guidelines on the interpretation of 
sequence variants, previous variant classifications may require modification due to 
increasing population data (Richards et al., 2015). In some cases, variants previously 
classified as ‘uncertain significance’ may now have enough supportive evidence to be re-
classified as either ‘benign’ or ‘pathogenic’. 
The increasing yearly rate of gene-disease discovery and increasing size of variant 
databases in combination with recently published WES reanalysis data has validated the 
usefulness of reanalysis for those who have not received a diagnosis from their initial 
WES results. Given that WES was first clinically offered in 2011, various laboratories 
and studies have only recently reported reanalysis diagnostic yield. According to one 
study, reanalysis of 40 WES data at a two to three-year interval could result in a 10% 
reanalysis diagnostic yield (Wenger et al., 2017). More recently, Ewans and colleagues 
(2018) found that reanalysis 12 months following initial WES results could have an 11% 
diagnostic yield in patients with Mendelian disorders, bringing their study of 54 
participants’ diagnostic yield from 30 to 41%. Another large-scale study completed in the 
United Kingdom reanalyzed 1,133 WES data finding a 13% reanalysis diagnostic yield 
(Wright et al, 2018). This means that up to 13% of families who did not receive a 
diagnostic result from their initial WES subsequently could receive a diagnostic result 
from reanalysis at least one year after the initial WES.  
1.9 Parental experience with whole exome sequencing 
 As previously mentioned, WES is indicated in cases of undiagnosed, medically 
complex individuals whose medical condition has not been identified through previous 
clinical or molecular investigations. The Undiagnosed Disease Network of the National 
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Institute of Health stated that “[Undiagnosed] patients have often spent years visiting 
medical centers and healthcare providers in different specialties across the country, 
accumulating large amounts of medical notes and test results, often at great emotional 
and financial cost” (Gahl et al., 2015).  
There have been several studies investigating the psychosocial effects of WES. 
Rosell and colleagues (2016) found that parents view the process of WES as a positive 
experience resulting in feelings of altruism and hope. In addition, the study found parents 
may feel a sense of duty to pursue WES to find a diagnosis, and the test can consequently 
influence medical care and reduce worry. Unfortunately, a positive result from WES or 
reanalysis may not provide information that may benefit a patient and their family. It is 
likely that if a causative variant is found from reanalysis of WES results, the condition is 
either extremely rare or newly discovered, leaving the family with a sense of isolation 
and frustration (Graungaard & Skov, 2007). 
On the other hand, the comprehensive nature of WES may give families false 
hope and cause feelings of disappointment following nondiagnostic results (Brett et al., 
2018). The dichotomy of emotions before versus after testing calls for a balance between 
hope and realistic expectations. Krabbenborg and colleagues (2016) found that WES 
results were associated with relief as well as worry, independent of the test result. When 
families received a conclusive diagnostic WES result, parents reported becoming more 
accepting, more informed on caring for their child, and better able to cope with perceived 
guilt. On the other hand, parents identified loss of hope in the recovery of their affected 
child and loss of social support surrounding the “new label”. Some parents felt they no 
longer belonged to patient organizations they previously participated in. Although some 
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felt a renewed sense of isolation, many were enabled to search for information regarding 
the child’s conclusive diagnosis, given by WES. While searching, many would come 
across blogs or Facebook pages and were able to establish new relationships with peers 
(Krabbenborg et al., 2016).  
Although many studies have looked at patient understanding and perception of 
initial WES, none to the researcher’s knowledge, have specifically assessed family 
response to and understanding of WES reanalysis. Based on the complex and differing 
perspectives of families living with undiagnosed conditions, it is essential to survey this 
population to shape current clinical practices and patient experience. In addition, it is 
important to identify gaps in knowledge and needed areas of growth in current practice 
when offering WES reanalysis. It is expected that WES reanalysis will continue as 
genomic testing becomes more accessible and as more information is gained.  
This population is unique and most have already completed previous genetic 
testing. Given that the initial WES process has been found to provide families hope, it 
was expected that WES reanalysis will yield a similar expectations of reanalysis. Also, it 
was expected that families will experience negative emotions following nondiagnostic 
reanalysis results. Those who had received a diagnosis from WES were expected to have 
had a more positive response to the testing than those who remained undiagnosed. The 
expected dichotomy of emotions before versus after testing provides an essential need to 
assess how to best counsel these individuals and families pursuing WES reanalysis.
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Chapter 2: Parental experience with whole exome sequencing reanalysis and 
its impact on the diagnostic odyssey1 
2.1 Abstract  
 Advances in genomic technology and an increase in the number of gene-disease 
associations have helped reduce the number of individuals living without a diagnosis. 
Whole exome sequencing (WES) analyzes the entire human exome in an attempt to 
determine if there is a molecular etiology for individuals who remain undiagnosed after 
other clinical or molecular investigations. Still, WES leaves most individuals 
undiagnosed, resulting in feelings of disappointment and uncertainty. Individuals who 
remain undiagnosed after WES can subsequently undergo WES reanalysis later due to 
improvements in bioinformatics, software updates, and an increase in known gene-
disease associations. This is the first study, to the investigator’s knowledge, which 
investigates parental perspective of those undergoing the most current genetic testing 
available. This study recruited parents of undiagnosed individuals who have completed 
WES and subsequent reanalysis through the Greenwood Genetic Center to investigate 
their response to and experience with WES reanalysis while on their diagnostic odyssey. 
Six semi-structured interviews were conducted, recorded, and transcribed verbatim. 
Transcripts were analyzed using grounded theory and assigned codes to meaningful 
segments of text. Results showed most participants had lower expectations of reanalysis 
                                                          




compared to the initial WES and felt it would not lead to a diagnosis. Most participants 
responded to nondiagnostic reanalysis results with feelings of disappointment and worry 
about the future. However, some exhibited a difference in the degree to which they 
negatively responded. Most participants recognized that reanalysis has been unhelpful for 
their child but expressed willingness to contribute to science if it will assist future 
individuals on a diagnostic odyssey. Despite feelings that reanalysis was unhelpful, most 
participants would consider reanalysis again for their child. Considering the apparent 
comprehensive nature of genomic testing, these results show there is a need to balance 
hope and realistic expectations during counseling and consent of WES reanalysis. In 
addition, parents desired ongoing medical support which can be offered through 
reanalysis. 
2.2 Introduction 
Advances in genomic technology and an increase in the number of gene-disease 
associations have helped reduce the number of individuals living without a diagnosis. 
Receiving a medical diagnosis can be beneficial for many reasons. A diagnosis can help 
direct treatment, aid in anticipatory guidance, determine prognosis, and influence family 
planning (Carmichael et al., 2015). The lack of a diagnosis can have various adverse 
effects for individuals and their families. This may include the inability to receive certain 
medical or educational services provided and covered by insurance or the state. 
Additionally, families may emotionally feel isolated, unable to connect with others living 
with a similar diagnosis, or have difficulty in coping with an uncertain future 
(Graungaard & Skov, 2007). 
The journey and search for a diagnosis is referred to in the clinic and literature as 
a “diagnostic odyssey” (Carmichael et al., 2015). Many individuals searching for a 
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diagnosis have been on a diagnostic odyssey for years. A diagnostic odyssey can be 
emotionally exhausting and financially costly for individuals and their families. A recent 
study found that undiagnosed individuals can be spending up to $21,000 searching for a 
diagnosis (Stark et al., 2017).  
Genetic testing is a quickly evolving field that many undiagnosed individuals 
have pursued. Whole exome sequencing (WES) first was offered clinically in 2011 and is 
just one example of genetic testing that undiagnosed individuals may pursue (Atwal et 
al., 2014). WES reads the entire human exome, which is the portion of all the human 
genome that codes for proteins made within the body. Therefore, WES analyzes a critical 
portion of the human genome.  
Indications of WES include cases of undiagnosed, medically complex patients 
whose medical conditions are unidentified through previous clinical or molecular 
investigations. Due to cost and amount of data sequenced, WES is recommended as one 
of the last steps in the search for a diagnosis (Stark et al., 2016). As WES and data 
analysis become more efficient and cost effective, its use in clinical genetic testing will 
become increasingly accessible. Currently, WES gives a molecular diagnosis in about 25-
40% of cases (Baldridge et al., 2017; Farwell et al., 2014; Lee et al., 2014; Yang et al., 
2014). Therefore, up to 75% of individuals pursuing WES remain undiagnosed.  
Patients who remain undiagnosed after WES can subsequently undergo WES 
reanalysis later. After a significant amount of time has passed, theoretically various 
factors such as the number of gene-disease associations have improved thus increasing 
the likelihood of finding a diagnosis. A database of human genes and genetic disorders 
and traits, known as Online Mendelian Inheritance in Man (OMIM), increased their 
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database with about 266 new gene-disease associations per year between 2004 and 2015 
(Wenger et al., 2017). As variant databases grow, laboratories will have the ability to 
update previous reports and variant classifications thus underscoring the importance of 
reanalysis of WES results.  
Although there are currently no published guidelines on WES reanalysis, 
laboratories may use their own guidelines for WES reanalysis, such as waiting at least 
one year between the initial test and the reanalysis (Williams et al., 2016). A recent study 
found that reanalysis at a one to two-year interval could result in a 13% reanalysis 
diagnostic yield (Wright et al., 2018). In other words, 13% of individuals who did not 
receive a diagnostic result from their initial WES were diagnosed after reanalysis. The 
increasing yearly rate of gene-disease discovery and increasing size of variant databases 
in combination with recently published WES reanalysis data has validated that reanalysis 
is useful in those who have not received a diagnosis from their initial WES results.  
It is further necessary to explore patient, or family, perspective of those 
undergoing WES and reanalysis. WES is not first-tier testing; therefore, this population 
was unique and had already completed previous genetic testing. Parents feel a sense of 
duty to pursue WES to find a diagnosis. Even when an individual receives a diagnosis 
from WES, the condition may be rare, leaving the family with feelings of frustration and 
continuing lack of anticipatory guidance (Graungaard & Skov, 2007).  
Because WES analyzes much more data than most other clinical and genetic 
testing options, the test can give these families hope after previous genetic testing has 
been inconclusive (Rosell et al., 2016). On the other hand, the comprehensive nature of 
WES may give families false hope and cause feelings of disappointment following 
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nondiagnostic results (Brett et al., 2018). The dichotomy of emotions before versus after 
testing calls for a balance between hope and realistic expectations.  
Although there have been several studies investigating parental perspective for 
those going through WES for the first time, none to the researcher’s knowledge, have 
assessed the impact that WES reanalysis has on undiagnosed individuals and their 
families. This study aimed to gain further insight into individuals and families who had 
received a negative, or nondiagnostic, test result from their initial WES and subsequently 
completed reanalysis. Compared to previous research on the topic, this qualitative study 
aimed to gain more in-depth knowledge regarding family emotions experienced after 
reanalysis, to understand the impact of the process and the results on the undiagnosed 
individual’s care, and to obtain the family’s response to the testing experience. 
Understanding factors associated with WES reanalysis may help medical 
professionals specifically address the needs of individuals pursuing reanalysis and help 
the families gain fulfillment and satisfaction from genetic services. Genetic counselors 
and other healthcare providers help counsel, interpret, or explain reanalysis results. By 
asking individuals and families about motivations, reactions, and the emotional impact of 
reanalysis, this study highlighted patient and family perceptions of the value this type of 
genetic testing has to offer. Identifying themes and experiences for those undergoing 
reanalysis may help genetic counselors to understand the needs to be addressed for this 
unique patient population. Therefore, this study aimed to provide guidance for genetics 
healthcare providers working with individuals and families pursuing the recent 
technology of reanalysis. 
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Given that WES has been found to provide families hope before testing, it was 
thought that WES reanalysis would have similar expectations preceding results. WES 
reanalysis is a facet of an already complicated, non-specific test. Therefore, it was 
difficult to know what their perception of and understanding behind reanalysis would be. 
Most families do not receive diagnostic results from WES, and even fewer receive 
diagnostic results from reanalysis. This study was expected to find frustration as a 
significant emotional response to nondiagnostic reanalysis results. It was expected that 
those who received a diagnosis from reanalysis would have a more positive response to 
the testing than those who remained undiagnosed. This was primarily an exploratory 
study, and its goal was to provide insight into a population that might benefit from 
meeting with medical professionals and to highlight unique areas of concern or interest 
that could be addressed by genetic counselors and other healthcare providers. 
2.3 Materials and Methods 
 The University of South Carolina Institutional Review Board reviewed the protocol 
and designated it as exempt from review in June of 2017. Greenwood Genetic Center’s 
(GGC) Clinical Genomic Sequencing Program Director, Dr. Julie Jones identified eligible 
participants. When WES reanalyses were completed, Dr. Jones sent a secure email to the 
ordering clinicians and genetic counselors, to recruit patients to the study. Eligible 
participants were recruited by phone using an original script (see Appendix A). The 
recruitment process took place from August 14, 2017 until February 14, 2018. For sample 
size calculation, the total number of eligible participants was provided to the primary 





 The inclusion criteria were as follows: 
 Individual, or caretaker of an individual, who has completed reanalysis of 
whole exome sequencing through Greenwood Genetic Center 
 Individual, or caretaker of an individual, who has received a diagnostic OR 
nondiagnostic reanalysis of whole exome sequencing 
 For individuals under the age of 18 who have completed reanalysis, their 
caretaker could participate   
 Individual who speaks fluent English 
The exclusion criteria were as follows: 
 Individuals under the age of 18 
The phone number and name of interested participants were obtained by their 
respective clinician and given to the PI through an encrypted email. Afterward, interested 
participants were contacted by the PI to determine a time for the interview.  
Semi-structured interviews were completed over the phone. Participation consent 
was obtained verbally at the beginning of each interview phone call by the PI reading aloud 
a standard script (Appendix B). Telephone interviews lasted up to 40 minutes. 
Demographic variables were collected and included gender, age, ethnicity, highest level of 
education attained, relationship status, location of residence, and number of children. In 
addition, participants were asked if their child’s reanalysis was diagnostic or nondiagnostic 
as well as when the initial WES and reanalysis was completed. GGC confirmed, or 
clarified, when each WES and reanalysis was truly completed. Key topics explored for 
qualitative analysis included participant understanding and expectation of reanalysis, 
response to reanalysis results, and any advice for medical professionals offering reanalysis.  
 
28 
 Interviews were recorded on the PI’s password protected computer using 
Microsoft Voice Recorder. Next, interviews were transcribed verbatim by the PI into a 
Microsoft Word document. For the responses collected from interviews, grounded theory 
methods were used to analyze the qualitative data. There were no preset themes for the 
study’s focus. The PI and an assistant independently identified and coded apparent 
themes from the participants’ responses and reported on their frequency. Kappa 
coefficient was calculated to be 0.605. To address the goals of this study, themes were 
identified among participant responses to compare them to previous literature published 
on parental experience with WES. Quantitative data was described by counting response 
types and through descriptive statistics (percentages and means). All identified themes 
and representative quotes can be found in Appendix C. 
2.4 Results 
 There were 25 total whole exome sequencing (WES) reanalyses completed by 
GGC of which 23 were eligible for this study. One of the 23 eligible families had 
significant psychosocial issues that their clinician and counselor felt would not lend 
themselves well to participate and, therefore, were not contacted. Thus, there were 22 
eligible participants for which contact was attempted by GGC clinicians and counselors 
between August 2017 and February 2018. The PI received eight verbal consents and 
successfully contacted six of the eight (75%). Therefore, this study successfully recruited 
six of the total 22 eligible (27%). All participants completed telephone interviews. Length 
of the interviews was between 14 and 38 minutes.  
 The sample had an age range of 22 to 45 years (average age of 34) and all were 
Caucasian females. The majority were married, had between 3 and 4 children, resided in 
South Carolina, and were college educated. There was a gender balance between males 
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and female children. None verbally reported that their affected child had a molecular 
diagnosis. One participant’s child had received a clinical diagnosis of Autism Spectrum 
Disorder (ASD) after reanalysis completion. She felt that clinical diagnosis explained her 
child’s full phenotype. Table 2.1 provides participant demographics. 
Table 2.1 Participant demographics (N=6) 
 
 On average, parents recalled expressing concern for their child’s symptoms at two 
months of age with a range from birth to six months. Data provided by GGC on the 
sample interviewed showed the youngest age at which initial WES results were reported 
was at 6 weeks and oldest 15.5 years of age (average age of 6). The youngest that 



















Ethnicity Caucasian  6 (100) 


























































 reanalysis results were reported in the sample interviewed was at 2.3 years and oldest 
16.9 years of age (average age of 7.8). The average time between a child’s initial WES 
and reanalysis was 1.75 years. All samples’ initial WES reports were issued between 
2015 and 2016. All reanalyses were reported between 2016 and 2018. Individual 
timelines can be visualized in Figure 2.1.  
 
 Figure 2.1 Individual timelines for each participant’s child. Figure adapted 
from Rosell et al., 2016.  
 
 The PI received unidentifiable WES and reanalysis results for the interviewed 
sample of six. Three of the six had normal initial WES results. The other three initial 
results detected variants but none explained the child’s phenotype. One child’s initial 
WES results found two variants in one gene; one pathogenic and the other a variant of 
uncertain clinical significance (VUS). These two variants were part of an ongoing 
research study taking place outside of GGC. The study’s goal was to investigate the 
effect of the two variants. The outside study had recently concluded that the two variants 
detected on the child’s initial WES were responsible for the patient’s full phenotype. 
Although this child now has a molecular diagnosis, the study participant and PI were 






















unaware of these findings at the time of the interview therefore, this participant’s child 
was undiagnosed during data collection. Individual WES and reanalysis results can be 
found in Table 2.2. 
 Three of the reanalyses did not detect any new variants. One of the initial WES 
that was negative detected a new VUS and a variant that partially explained the child’s 
phenotype. This was not reported verbally to the PI by the participant during the 
interview. The other two reanalyses detected new information including variants of 
uncertain significance (VUSs) and a heterozygous pathogenic variant associated with 
autosomal recessive disease. Neither of those two reanalyses detected variants thought to 
be responsible for the child’s phenotype. Overall, half of the reanalyses gave the family 
new information but none leading to a complete explanation of phenotype.  
 Presented below are five main themes found describing parental understanding of 
reanalysis, response to, and impact of reanalysis results. Key themes found include 
expectation of reanalysis, negative emotional response to results, acceptance, altruism, 
and support. Subthemes are described in each section.  
 2.4.1 Expectation of reanalysis. Five of six participants understood why 
reanalysis of initial WES data might yield a diagnosis after previous WES results had not. 
One was unsure why the reanalysis was useful. Four participants explained that there 
have been new advances in technology and new gene discoveries over the last few years.   
Why don’t we just do this again to make sure there is nothing else, you 
know. And there were some new advances in the past couple of years. 
That maybe it could ...detect things that it couldn’t detect a couple years 


















*WES was completed on amniocytes  
Abbreviations: Diff=different; assoc=associated; AR=autosomal recessive; XLR=X-linked recessive
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2 VUS assoc. with AR 
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variants in trans in one gene 
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 Similar responses acknowledged advancements in science as the main reason for 
missing anything the first time. Those responses explained reanalysis as a way to “double 
check” results as opposed to advancements in technology driving reanalysis. Overall, all 
but one response described that reanalysis had the ability to detect or reclassify a 
previously undetected or unknown variant. One of the participants opted in to secondary 
findings during the reanalysis. Participant reasons for reanalysis can be found in Figure 
2.2.
 
Figure 2.2 Participant reason for reanalysis. Improved detection included gene discovery 
and improvements in technology.  
 
 Although all but one participant noted they remained hopeful of finding a 
diagnosis, some had differing levels of expectations which ranged from low to high 
expectations that reanalysis would provide a diagnosis. A low level of expectation was 
assigned when the participant did not expect that reanalysis would lead to a diagnosis. A 

































would yield a diagnosis but still felt there was a chance. A high level of expectation was 
assigned when the participant reported that they felt reanalysis would lead to a diagnosis. 
Finally, a neutral level of expectation was assigned when the participant could not 
comment either way on level of expectation. Level of expectations of each participant can 
be seen in Table 2.3. One participant held high expectations due to her understanding of 
reanalysis.  
...because they were like, uhm, you know, we’ve made leaps and bounds 
in two years and you know, hopefully something is going to come up or 
not come up so we can know it’s not there, you know. I think I put even 
more into it this time because it’s been two years and they’ve made a ton 
of progress. Participant 2, 2-year-old daughter 
Two of the participants expressed moderate levels of expectation for reanalysis. One felt 
that reanalysis was an afterthought, leading to a low expectation.  
 Reanalysis was kind of like okay were going to do that again, no big deal. So, it 
 wasn’t as big of a deal. Participant 4, 5.5-year-old daughter  
Two had neutral expectations, one of which was unsure about why reanalysis was 
completed and the other had a similar confusion about reanalysis.  
Table 2.3 Participant expectation of reanalysis  
 
Sex of child 
Age of child 
at interview 
Time between initial 
WES and reanalysis 



























 Participant hope for a diagnosis changed from WES to reanalysis. One participant 
recalled how expectations were different during the initial WES compared to reanalysis.  
I guess I should say expectations were different. I was hoping on the first 
one that we would get answers and on the second one felt more like I 
didn’t expect that we would find anything. So, by that point we’ve tried 
everything we can...so I see that I was really hopeful we would get 
answers. Participant 6, 4-year-old son 
 In addition to retaining hope in the presence of lower expectations, was 
the obligation to pursue testing. All but one participant would reconsider 
reanalysis again for their child if it had a chance of finding a diagnosis. When 
asked if they would consider reanalysis again, participants responded that they 
feel they should try everything, especially if a medical professional feels it might 
be beneficial. They felt a duty to complete any testing that might lead to a 
diagnosis, including reanalysis. These responses expressed some degree of hope 
that reanalysis may lead to diagnosis at some time. One participant who was 
unsure if they would pursue reanalysis further explained her child was diagnosed 
recently with ASD and felt there was no need to pursue further genetic testing.  
 Similarly, when participants were asked to provide advice to other 
families pursuing reanalysis many emphasized the role of positivity and hope, 
even if expectation of WES had decreased. Two of the participants expressed a 
duty and obligation to pursue all recommended testing and to keep trying. 




 2.4.2 Negative emotional response to results. All participants verbally stated 
WES and reanalysis had not provided a diagnosis for their child. When participants were 
asked to describe their reaction to the reanalysis test results, most recalled an immediate 
negative emotional response to the results. The overall negative emotion associated with 
these results was disappointment. Disappointment was accompanied by frustration, guilt, 
and worry.  
I know it’s not my fault but I feel like it’s my fault... I remember being a 
little upset when I got the results back because they could say, again, you 
know, that it was from me. Participant 1, 8-year-old son 
Common concerns following results included worry about the life expectancy, treatment, 
and recurrence risk. In this way, reanalysis elicited more questions than answers just as 
the initial WES had. 
Also felt like his future was really uncertain. So like some genetic 
disorders you find out and like they have a low life expectancy. They’ll 
never, you know...and like knowing that that was possible, that we had no 
way of knowing, felt really disconcerting. And it probably took us a few 
months to say out loud, “will he ever leave our house? Or will he be an 
adult needing to be cared for?” ...sort of what we have found is that there’s 
more questions than answers. Participant 6, four-year-old son 
 A subtheme noted was a difference in the degree to which a negative response 
was elicited compared to the initial WES results. Most participants did not have as much 




I felt like we got the big blow of that there is something happening the 
first time. So that like scariness of okay this is real, happened the first 
time. And so the second time I didn’t have that same surprise of like okay 
there is something going on. Before I didn’t think there was. Participant 6, 
4-year-old son 
Participants felt that they had been through this testing before; therefore, receiving 
negative, nondiagnostic results was not as disappointing as the first WES results.   
 On the other hand, one participant felt she had been given false hope and, 
therefore, had an enhanced negative emotional response of frustration.  
Frustrated! Because we haven’t really asked for any of this stuff...it’s not my fault 
that the geneticists haven’t caught up yet, to find out what she has to give it a 
name. Participant 2, 2-year-old daughter 
Two participants noted that lack of financial burden affected how they perceived 
this testing. It is important to note that GGC did not bill insurance or the patient 
for reanalysis. Therefore, these participants did not have a financial burden from 
reanalysis. Although cost associated with the initial WES was not a focus of this 
study nor discussed during interviews, participants mentioned that finances would 
affect decision-making during the course of WES and reanalysis. One admitted 
that if they had paid for reanalysis themselves, they would not make the test a 
priority because they do not have much faith in the test to find a diagnosis after 
negative initial and reanalysis results.  
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I don’t think we would have run the reanalysis if…I know we 
wouldn’t have run the reanalysis if there had been a financial piece 
on us. Participant 6, 4-year-old son 
 The others knew that they would have been even more disappointed with 
the nondiagnostic results but knew they would pursue reanalysis again if the 
doctors ever felt reanalysis would be helpful.  
If I had paid the big bucks, I probably would have been very 
disappointed ...you still feel like you threw your money away. But 
it is worth it, ‘cause you want to know. Participant 4, 5.5-year-old 
daughter 
 Furthermore, GGC does not bill for reanalysis, therefore none of the participants 
had paid for reanalysis.  
 2.4.3 Acceptance. Present in all the interviews was a theme of acceptance. At 
some point on their diagnostic odyssey, these families have accepted they will likely not 
receive a reason or name for their child’s diagnosis. Because these families have been 
undiagnosed for years, they have been learning to cope with uncertainty. Results from 
reanalysis are coming at a time when they have already dealt with the initial shock that 
their child will be living with a medical condition for the rest of their lives. In this way 
they have become resilient to disappointing test results.  
It’s just been a long 18-year journey with her. And I just pretty much went 
on ahead and accepted her for the way she was. And how she was going to 
be. And I just took it day by day with her…I don’t get my hopes up for 
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nothing, because I’ve learned that when she was a baby. So I just take it as 
it comes. Participant 3, 18-year-old daughter 
 By the time of reanalysis they have accepted this is how their child will be and 
shifted the majority of their focus on treating their child, rather than fixating on a 
diagnosis.   
‘Cause, you know, it’s like the first time you’re really talking about like 
there’s definitely something wrong with my kid, like it’s a fact and you’re 
still accepting it. I think by the time exon sequencing results come in we’d 
been dealing with this for a couple of years. And we kind of hardened, and 
kind of like much more like not surprised by stuff. Participant 4, 5.5-year-
old daughter 
 Although participants exhibited acceptance of not finding a diagnosis, participants 
noted that staying positive is how they cope with nondiagnostic results.  
Well I’m trying to look at it in a positive way, and not findings some 
answers have been a good thing... So I’m trying to look at it that way, that 
no answer is a good answer... I’m still staying positive on it...we’re just 
going to keep doing what we’re doing. Hopefully one day we’ll figure it 
all out. Participant 1, 8-year-old son 
 2.4.4 Altruism. All participants expressed that WES and reanalysis has been 
unhelpful for their own child. Although the testing was felt to be unhelpful, none 
regretted completing the testing. Half expressed if the testing was not hurting their child 
and data might help future families then it was worth it.  
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I think eventually if it doesn’t help [our daughter] it’ll help someone else 
...if it keeps one other person, eventually down the road, from having this 
then, or from having to deal with it without a name, then it’s worth it. 
Participant 2, 9-year-old daughter  
 Some understood that this testing may aid in new discoveries which was 
enough reason to pursue testing.  
We both sort of got to a place of like I mean that’s fine we can keep 
digging in for science sake but it doesn’t seem to be really helping [our 
son]. Participant 6, 4-year-old son 
 2.4.5 Support. When asked what was helpful during WES reanalysis, participants 
expressed the important of immediate and ongoing communication from the genetics 
community. Immediate support was desired in the form of clear communication and time 
spent explaining the test during appointments. Three of the participants felt their genetic 
counselor and geneticist clearly communicated why reanalysis might be beneficial. When 
families felt the medical professionals would take the time to explain WES and 
reanalysis, participants noted an appreciation for honesty and realistic expectations. 
I think the biggest thing is being clear up front, which they were. Is that 
you may not get anything out of this. You still may not have an answer. 
Participant 4, 5.5-year-old-daughter 
 Not only was immediate support during appointments important but ongoing 
support was desired through email and telephone. One participant felt strongly about her 
genetic counselor’s ongoing availability to answer questions.  
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And I could call 50 times and she would still answer the questions. And I 
think that’s really big because sometimes when we come in and we talk to 
you guys and you tell us all this stuff and we’re just trying to process that 
our kid has something and it might not be that day that we realize we have 
a question. We need to know that we can call back and ask those questions 
and you’re not going to be upset and that you’re going to answer them. 
Participant 2, 9-year-old daughter 
2.5 Discussion 
 The population interviewed is unique because these families have pursued many 
clinical and genetic tests which have not led to a diagnosis for their child. When one of 
the most comprehensive genetic tests available such as WES reanalysis does not lead to a 
diagnosis for their child, parents may find themselves with more questions than answers. 
This poses new challenges not only for families undergoing reanalysis but also for 
medical professionals offering reanalysis. Similar to previous studies investigating 
parental experiences with WES, responses supported that reanalysis can give families 
hope of findings a diagnosis (Rosell et al., 2016). In addition, responses supported that a 
negative emotional response follows nondiagnostic test results (Brett et al, 2018; 
Krabbenborg et al., 2016).  
 This is the first study to identify parental understanding, response to, and impact 
of WES reanalysis that the principal investigator is aware of. Although this study was 
exploratory and completed on a small sample, it provides insight on essential aspects 
including psychosocial implications and parental experience that should be taken into 
consideration when offering reanalysis to individuals and families. 
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 2.5.1 Practice implications. Most participants had some level of understanding 
as to why reanalysis might lead to a diagnosis after previous WES had not. In accordance 
with a previous study investigating parental understanding of initial WES, this study 
indicated that this sample received effective pre-test counseling that explained reanalysis 
(Tolusso et al., 2016). Responses also showed parental understanding of reanalysis likely 
influenced their expectation that reanalysis would lead to a diagnosis. It appeared that 
those who appropriately understood that reanalysis might not lead to a diagnosed reported 
a low to moderate expectation. For the majority of participants, their expectations of 
testing were not higher than their initial WES.  
 On the other hand, one participant reported a high expectation due to her 
understanding that there have been numerous advances made within the last few years. 
She had a similar, if not higher, level of expectation to the initial WES. This perception 
of reanalysis led to a feeling of false hope. Brett and colleagues (2018) recently identified 
balancing hope and expectations during the course of genomic testing being a significant 
counseling challenge. These results further emphasize the importance of balancing hope 
with realistic expectations while counseling these families. Being honest with parents 
during pre-test counseling is equally important as instilling hope. One suggestion might 
be to present the diagnostic yield of reanalysis being approximately 10% based on recent 
research (Wenger et al., 2017; Wright et al., 2018). In this way one can inform them that 
reanalysis may not lead to a diagnosis and can let them develop an informed perception 
of reanalysis. 
 Similar to initial WES results, when reanalysis did not lead to a diagnosis there 
was an immediate negative emotional response (Brett et al., 2018; Graungaard & Skov, 
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2007). Although the type of emotional response did not change from the initial WES to 
the reanalysis, the degree to which the results elicited a negative response did change. 
Most participants expressed there was less of a negative emotional response following 
reanalysis than the initial WES. There were no new emotions identified. Participants 
likely had a different degree of response because they had previously experienced 
nondiagnostic results from this testing and were prepared to receive similar results. 
Although these participants seem to already possess the ability to cope with these types of 
results, it is still necessary to prepare them for nondiagnostic reanalysis results. This 
should be done to avoid exacerbated negative feelings that follow false hope. 
 Furthermore, the degree to which parents negatively responded differed from their 
initial testing depending on their perception of reanalysis. This was observed in the 
participant who expressed high expectations of reanalysis. When holding high 
expectations of reanalysis, she experienced a heighted negative emotional response to 
reanalysis. This further bolsters the need to give realistic expectations of reanalysis. 
Although one cannot predict how a parent will respond to negative results, medical 
professionals should consider how they can present reanalysis to help families properly 
respond to nondiagnostic results.  
 A second aspect found to influence the response to reanalysis results was where 
the parents were on the timeline of their diagnostic odyssey. At some point these families 
have accepted they may not find a diagnosis for their child’s condition. Acceptance may 
come at different times for different families but by the time they are pursuing reanalysis 
they have dealt with disappointment from previous experiences with testing. Through 
these disappointing experiences, they have learned to accept an uncertain future. 
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Although these families have accepted an uncertain future, pursuing reanalysis can 
remind them that the genetic community has not given up on finding a diagnosis for their 
child. 
 While many participants felt reanalysis was unhelpful for their child this study 
found that most would consider reanalysis again for various reasons. Like Rosell and 
colleagues (2016), this study found that parents feel an obligation to try everything 
possible that could help diagnose their child’s condition. The hope for a diagnosis 
outweighed their negative response to the results. A second reason for pursuing 
reanalysis was a desire to help families in the future. This indicated altruism and a desire 
to help others even when testing has been unhelpful for themselves. Despite a negative 
emotional response, participants were motivated by the possibility to help future families 
in similar situations to them. It may be beneficial for all ordering providers to explain 
how their child’s reanalysis may aid in future discoveries and help future families receive 
a diagnosis. This may be through reanalysis or offering data be used in research.  
 Interestingly, a reason participants noted that they might not pursue reanalysis 
again is if there was a financial burden. None of the participants paid out-of-pocket for 
reanalysis and, therefore, there was no cost burden to outweigh the possible benefits of 
testing. Some mentioned that if they had to pay they would have struggled more with the 
decision to pursue reanalysis. With a diagnostic yield of 13%, these families may not feel 
reanalysis would be worth it if they had to pay. Although GGC does not currently charge 
for reanalysis, this may be pertinent for families completing reanalysis through other labs 
as some will charge for reanalysis or have differing billing policies surrounding 
reanalysis. This might change the extent to which these families feel reanalysis is an 
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option. In addition, it is possible families would have greater expectations or negative 
emotional responses if they are financially, not only emotionally, invested in the testing.  
 Importantly, participants noted an appreciation for immediate and ongoing 
support during their experience with reanalysis. Immediate support was desired during 
appointments by medical professionals taking the time to explain reanalysis and identify 
risks versus benefits. This is similar to any pre-test counseling offered to these families. 
Ongoing support was appreciated through knowing a medical professional was available 
for these families to reach out to when needed. In this study, a genetic counselor was the 
medical professional managing their testing and fielding questions from these 
participants. It was important that these families knew they could call or email to ask any 
medical question, as these questions frequently arose after appointment times. After 
experiencing care with other specialties, these participants felt genetics understood the 
need for immediate and ongoing support. It was comforting to the families that a medical 
professional recognized the need for support outside of their appointment. This ongoing 
support seemed to reduce some emotional burden found to be associated with being 
undiagnosed. 
 Different from any other testing available, reanalysis itself is a form of ongoing 
support for these families after comprehensive WES results have not led to a diagnosis. 
The test lets families know there may be something more to offer them in the future. It 
acts as a reminder that their care team has not forgotten about them. Results indicated that 
although they remained hopeful for a diagnosis, they did not feel a diagnosis was 
essential at this point in their child’s life. At this point in their odysseys most had 
accepted that they will not receive a name for their child’s condition. Although the results 
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from reanalysis are important when yielding actionable results, these families may be 
best served by the support they feel from the medical community through reanalysis.  
 2.5.2 Study limitations. Several factors may have influenced these results. First, 
the study had a small sample size that were eligible through one institution, GGC. GGC 
is one lab of many who offers WES and reanalysis. All labs have unique WES and 
reanalysis procedures, billing policies, and diagnostic yields. As discussed previously, 
financial burden may largely influence the expectation and response to reanalysis results. 
Surveying a sample that has completed reanalysis through a different lab may yield 
different responses. Similarly, all reanalyses were offered by geneticists and genetic 
counselors employed by GGC. Therefore, pre-test and case management is likely similar 
for this entire sample. In reality, many different geneticists and genetic counselors are 
offering reanalysis; therefore, those pursing reanalysis may have different experiences 
than this sample. All these factors, including the small sample successfully recruited, 
makes these results difficult to generalize to all who have completed reanalysis. Finally, 
this study did not gather responses from reanalysis that resulted in a diagnosis; therefore, 
data were unable to establish differences between diagnostic and nondiagnostic reanalysis 
results. 
 2.5.3 Future research. A study including more participants, with reanalysis 
ordered from different institutions, and through different laboratories would be 
worthwhile as it would allow for greater insight and generalizability of results. Similarly, 
collecting responses from families who have received a diagnosis through reanalysis to 
compare nondiagnostic and diagnostic reanalysis experiences would be helpful. Based on 
responses gathered in this study, it would also be useful to survey the role of financial 
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burden of reanalysis. Finally, it would be interesting to evaluate counselor presentation 
versus family perception of reanalysis to assess what patients are being told about 
reanalysis compared to what they are truly retaining.  
2.6 Conclusions 
 Whole exome sequencing and subsequent reanalysis is one of the most 
comprehensive tests that can be offered to individuals who are living undiagnosed with 
complex conditions. Families of those living undiagnosed can be accompanied by 
adverse emotions including uncertainty, worry, and feelings of isolation. Due to an 
uncertain future and feelings of isolation, support for these families is essential. Genetics 
is a unique facet of healthcare that interact with these families. Genetic counselors and 
other genetics professionals are in a pivotal role to offer immediate and ongoing support 
to the undiagnosed population. Although these families may have accepted that they will 
not find a diagnosis, they should not be forgotten. From this research it is important to 
recognize that these families see reanalysis as a form of ongoing support.  
 Despite negative emotional responses to initial WES results, the hope for a 
diagnosis was still present enough to pursue testing such as reanalysis. Most of the 
participants noted that they did not have as high of expectations for reanalysis to lead to a 
diagnosis as they did the initial WES. These families also recognized that reanalysis may 
not be helpful for their child but were willing to complete reanalysis with the idea the 
data may help future families. These results emphasized a need to balance parental hope 
and realistic expectations of reanalysis. Participants appreciated honesty regarding 
reanalysis. Specifically informing parents that reanalysis has a relatively low diagnostic 
yield may help mitigate negative responses to nondiagnostic results.  
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 Although this study cannot be generalized to all completing reanalysis, it provides 
preliminary insight into parental experiences with reanalysis. As more WES tests are 
completed, reanalysis will become more frequent. Knowing how to navigate complex 
factors such as parental emotions and questions regarding reanalysis is key to providing 
these families with the support they need. 
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Chapter 3: Conclusions 
 Whole exome sequencing and reanalysis is one of the most comprehensive tests 
that can be offered to individuals who are living undiagnosed with complex conditions. 
Families of those living undiagnosed can be accompanied by adverse emotions including 
uncertainty, worry, and feelings of isolation. Due to an uncertain future and feelings of 
isolation, support for these families is essential. Genetics is a unique facet of healthcare 
that interact with these families. Genetic counselors and other genetics professionals are 
in a pivotal role to offer immediate and ongoing support to the undiagnosed population. 
Although these families may have accepted that they will not find a diagnosis, they 
should not be forgotten. From this research it is important to recognize that these families 
see reanalysis as a form of ongoing support.  
 Despite negative emotional responses to initial WES results, the hope for a 
diagnosis was still present enough to pursue testing such as reanalysis. These results 
emphasized a need to balance parental hope and realistic expectations of reanalysis.  
Participants appreciated honesty regarding reanalysis. Although families may experience 
a negative emotional response to nondiagnostic reanalysis results similar to that of initial 
WES, they likely will not feel the emotional response to the same extent felt after the 
initial results. Specifically informing parents that reanalysis has a relatively low 
diagnostic yield up to 13% may help mitigate negative responses to nondiagnostic results.  
 Interestingly, these families also recognized that reanalysis may not be helpful for 
their child but awere willing to complete reanalysis with the idea the data may help future 
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families. Providers can inform parents how their child’s reanalysis data may be used in 
research and subsequently help future families. 
 Although this study cannot be generalized to all completing reanalysis, it provides 
preliminary insight into parental experiences with reanalysis. As more WES tests are 
completed, reanalysis will become more frequent. Knowing how to navigate complex 
factors such as parental emotions and questions regarding reanalysis is key to providing 
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Appendix A – Consent completed by GGC healthcare provider 
You are agreeing to be contacted by Nicole Larsen, a genetic counseling graduate 
student, with the interest in participating in a school research project. Your phone number 
and name will be given to Nicole Larsen upon consent. Nicole will contact you to set up a 
time for a phone interview. Your participation in this project is voluntary. Consent to 
participate will be completed upon the beginning of the interview phone call.  
 
 
Name of clinician or genetic counselor obtaining consent: ____________ 
 
Name of interested participant: _____________ 
 
Phone number of interested participant: _____________ 
 








Appendix B – Participant consent completed during interview 
Consent statement 
You are agreeing to participate in a telephone interview as a part of a genetic counseling 
graduate school research project. This interview will last approximately 45 minutes to 1 
hour. Your participation in this project is voluntary. You may withdraw from the study at 
any time. If at any time there is a question you are not comfortable answering, please let 
me know and we can proceed on to the next question. While no direct benefit may be 
observed, this study may provide future benefit to others pursuing WES reanalysis and 
medical professionals working with them. The risk for participating in this study are 
minimal.  
 
With your consent, this conversation will be recorded and transcribed. All responses 
gathered from the interviews will be kept anonymous and confidential. If a quotation is 
used from this interview, all identifying information will be removed and you will be 
assigned an alternative name.  
 
If you have any questions regarding this research, you may contact either myself or my 
faculty advisor, Emily Jordon, MS, CGC. If you have any questions about your rights as 
a participant, you may contact the Office of Research Compliance at the University of 
South Carolina at (803)777-7095. 
 
Do you consent to this research study? Date: _______ Time: _____
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Appendix C – Themes 
Table C.1 Overall themes 
Theme Subtheme 
Expectation of reanalysis Understanding of reanalysis, hope for a 
diagnosis, obligation   
Negative emotional response to results Disappointment, worry, guilt, degree of 
response elicited 
Acceptance Uncertainty, time spent on diagnostic odyssey  
Altruism   
Future families, aiding in gene discovery 




Table C.2 Themes with representative quotes 
















“Yeah there is always something new coming up so...everybody is always making a 
breakthrough on something.” Participant 3 
 
“I guess they just wanted to make sure they wasn’t missing anything. I guess, I don’t 
know.” Participant 5 
 
“I was still just hopeful but more patient this time.” Participant 1 
 
“I was hoping on the first one that we would get answers and on the second one felt 
more like I didn’t expect that we would find anything.” Participant 6 
 
“[we would consider reanalysis] if they ever felt like it would be worth it for them to 
reanalyze, or it would be help.” Participant 2 
Negative emotional 
















“...hoping that there was one magic bullet that was going to explain everything...and 
there isn’t. So just disappointment with that. Participant 6 
 
“What are you supposed to do if you can’t tell somebody what’s wrong...it’s been 
very heartbreaking to see that and not put a name on it.” Participant 2 
 
“My reaction was like “that’s fine but what do we do from here?” Participant 6 
 
“Not that I ever thought we’d get a diagnosis and be like “oh let’s fix her.” But more 
to be able to say, “Okay, this is what she has, let’s looks at other people with the same 
condition. What is their life expectancy, what other organ systems get involved?” You 
know, what are some things that come up in the future?” Participant 4 
 
“Seeing that something came from me that I could see potentially in him was a little 








Degree of response 
 
 
“A little disappointment, but I kind of knew a little bit going into it that. Kind of went 
into it knowing that it may not give us an answer. So I think we’d already come 
prepared for that. So a little disappointment but also expecting it at the same time.” 
Participant 4 






Time spent on odyssey 
 
 
“I think some days I would want to know this is the path, even it’s the worse news 
possible.... but when he’s progressing I don’t want that at all. I’m like “He can do 
anything! We’re totally good.” But when it feels stale like when he’s not progressing 
or when we just have more concerns than we have answers then yes. I just would 
rather just have answers even if it’s worse case scenario.” Participant 6  
 
“It really didn’t bother me, because it’s just been a long 18-year journey with her. 
And I just pretty much went on ahead and accepted her for the way she was.” 
Participant 3 
 
“I think we are much more resistant. By the time we had got the results, we had kind 
of weren’t as impacted by things as we used to be.” Participant 4  




“…but if it keeps one other person, eventually down the road, from having this then, 
or from having to deal with it without a name, then it’s worth it.” Participant 2 
 
“They’re constantly finding out new things. You know, that trying again is never 
really a bad thing. Even if you’ve done it once and found nothing. You can do it again 
and find more information.” Participant 1 







“I appreciate that in every appointment I feel like they’ve taken a lot of time with us. 
And that was really helpful because it is really heavy information and...they’ve 
always done a really good job at slowing it down. And explaining to us, without 
talking down to us.” Participant 6 
 
“Trust that everyone has your child’s best interest in mind, even if it’s information 
that’s hard to hear.” Participant 6 
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